H IV-1 infection, via activity of viral protein Nef, impairs cholesterol efflux mediated by the cholesterol transporter ATP-binding cassette A1 (ABCA1). 1 ABCA1 is the main cellular cholesterol transporter regulating delivery of cellular cholesterol to extracellular acceptor, apolipoprotein A-I. Studies in animal models demonstrated that this activity of Nef may be responsible for hypoalphalipoproteinemia and high risk of atherosclerosis observed in HIV-infected subjects. [2] [3] [4] Our recent study identified calnexin, an integral endoplasmic reticulum (ER) membrane lectin-like chaperone, as a key player in the mechanism of Nef-mediated inhibition of ABCA1 and cholesterol efflux. 5 Calnexin and its homologue calreticulin regulate folding and maturation of newly synthesized glycoproteins by engaging them in a calnexin/calreticulin cycle. 6
calnexin expression by RNAi resulted in a significant decrease in functional activity of ABCA1, evidenced by reduced cholesterol efflux to ABCA1-specific acceptor apoA-I. 5 We also showed that Nef impairs the interaction between ABCA1 and calnexin, and this effect of Nef is essential for the inactivation and downregulation of ABCA1. 5 Importantly, the inhibition of ABCA1-calnexin interaction by Nef is specific, as interaction between ABCA1 and 2 other proteins, dystrophin and serine palmitoyltransferase, shown previously to bind ABCA1, 10 was not affected. Also not affected was the interaction between calnexin and HIV-1 envelope glycoprotein, gp160; in fact this interaction was even enhanced by Nef. 5 These findings suggested that Nef modulates the activity of calnexin, but the mechanism of this effect and molecular details of Nef/ calnexin interaction remained unknown. Moreover, it was unclear whether the interaction between Nef and calnexin is direct, making screen for inhibitory compounds difficult.
Calnexin is a 592-amino acid type I transmembrane protein composed of 3 parts: a lumenal fragment consisting of a globular β-sandwich domain responsible for the interaction with carbohydrates and a proline-rich tandem sequence repeat domain (the P domain) involved in protein-protein interactions, a transmembrane domain, and a cytoplasmic domain of 90 residues. 11, 12 The cytoplasmic tail of calnexin can undergo phosphorylation and palmitoylation which regulate calnexin association with several proteins and protein complexes that influence functional activity of this chaperone. [13] [14] [15] [16] [17] [18] For example, palmitoylation of the C-tail of calnexin mediates its association with the ribosome-translocon complex, which is essential for the ability of calnexin to capture its client proteins as they emerge from the translocon. 18 Ribosome association of calnexin is also regulated by phosphorylation on Ser534 and Ser544 by casein kinase 2 and on Ser563 by protein kinase C/prolinedirected kinase. 11 In addition, phosphorylation at Ser563 has been shown to play an essential role in quality control function of calnexin. 15 Therefore, the C-tail of calnexin may play a functional role in regulating the activity of the chaperone both directly, by affecting ER lumenal events involving calnexin, and indirectly, via modification of calnexin localization in the ER.
Here, we demonstrate that the C-tail of calnexin is targeted by the HIV-1 protein Nef, which uses this interaction to disrupt calnexin-assisted maturation of ABCA1 and impair cholesterol efflux. We characterize the important structural features of the Nef/calnexin interaction and identify a small molecule compound that blocks this interaction and reverses negative effects of HIV infection on cellular cholesterol metabolism.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Cytoplasmic Domain of Calnexin Is Necessary for Interaction With Nef
In our previous study, we have shown that HIV-1 Nef interacts with the ER chaperone calnexin. 5 To test which region of calnexin is necessary for binding to Nef, we used calnexin constructs that had deletion of the lumenal repeat segment (aa 276-409) or truncation of the C-terminal cytoplasmic domain (aa 504-586; Figure 1A ). We cotransfected human embryonic kidney (HEK) 293T cells with Nef cons -expressing vector and HA-tagged variants of wild-type (WT) calnexin or the deletion mutants and performed coimmunoprecipitation. Figure 1B shows that WT calnexin interacted strongly with Nef, whereas calnexin construct with internal repeat motif deletion (CNX ∆276-409 ) exhibited partially reduced binding (40% reduction). However, binding of Nef to calnexin construct carrying the truncation of the C-terminal cytoplasmic tail (CNX ∆504-586 ) was reduced dramatically (70% reduction). This finding highlights the importance of the cytoplasmic region of calnexin in interaction with Nef. The role of calnexin cytoplasmic tail in the interaction with Nef is consistent with Nef's predominant localization to the cytoplasm 19 and with the charges of the interacting domains: the cytoplasmic domain of calnexin is composed mainly of negatively charged amino acids, which may promote interaction with the N-terminal region of Nef (see below) enriched in positively charged residues. The modest effect that deletions in the lumenal repeat motif of calnexin had on Nef binding (40% reduction of binding), and residual binding (30%) of Nef to calnexin construct with deleted cytoplasmic domain, may be because of artefacts caused by overexpression. In addition, mutations in the lumenal domain may affect binding properties of the cytoplasmic domain via reverse signal transduction mechanism (Discussion section of this article). These results provided an initial lead, which was followed in subsequent experiments.
Computational Model of Nef-Calnexin Interaction
Experimentally solved molecular structure of calnexin is available only for the lumenal domain, 12 and to obtain 3-dimensional structure of calnexin cytoplasmic domain we performed its modeling with several modeling servers implementing different methods, which produced several models ranging from the fully folded structures to structures that included natively disordered regions. The models have been assessed for accuracy and the final round of modeling was performed with the server QA-RecombineIt. The final model had a loosely folded structure (Figure 2A , a). Computational prediction of Nef-calnexin complexes showed Nef N-terminal α-helix forming the interaction interface with calnexin cytoplasmic domain (Figure 2A , b and c). In comparison with the calnexin cytoplasmic domain model, the model of Nef was based on several experimental structures [20] [21] [22] [23] [24] and thus had better accuracy. Nef-calnexin interaction has been modeled by global docking using four different docking servers: Cluspro, HEX, SwarmDock, and Zdock. A combined set of the best Nef-calnexin docking models produced with these servers contained 80 models. The advantage of this approach is that the resulting models represented Nef-calnexin interaction modeled by four different, unrelated methods and, therefore it was more reliable than using a single server. From these, 49 models have been filtered out as possibly interfering with interaction of Nef with ER membrane. Intermolecular interactions in the remaining subset of 31 models have been identified. There are several distinct clusters of interactions, with sharp maxima for Lys7 and Arg in positions 8, 19, 22, 75 , and 109 ( Figure 2B ). Notably, similar analysis of interactions performed on the full initial data set of 80 docking models showed similar clustering and maxima (not shown). We can therefore hypothesize that the identified residues represent the overall favorable Nefcalnexin interaction sites. All these residues, except Lys7 and Arg8, have been also identified as participating in interactions in the experimental structures of complexes which included Nef (Table) . A representative model of Nef-calnexin binding is shown in Figure 2A , b and c. Analysis of the conserved residues in Nef performed with ConSurf 25 revealed several such conserved positions in the N-terminal region, including Lys4, Ser6, Lys7, and Arg19. Multiple sequence alignment of the human HIV Nef sequences from Uniprot showed that Lys7 is highly conserved across the spectrum of HIV-1 and HIV-2 sequences. Conserved residues indicate structurally and functionally important positions, including interaction sites. Therefore, Lys7 represents a new interaction site predicted by us, which was not previously identified in Nef interactions with other proteins (Table) .
Nonstandard Abbreviations and Acronyms
Lysine Residues of Nef in Positions 4 and 7 Are Critical for Nef-Calnexin Interaction
From the perspective of drug design, targeting viral proteins has lower potential for side effects than targeting cellular partners. We thus focused our efforts on Nef. According to docking modeling and sequence conservation results, Lys7 possibly represents a new binding site in Nef, and accordingly it has been selected for mutagenesis experiments. Lys4 has been also selected because it is a Lys7 near-neighbor and, as demonstrated in the Nef model, it plays a key structural role for the N terminus (Figure 2A, d) . Therefore, mutation of both Lys4 and Lys7 was predicted to invoke structural rearrangement in the Nef N-terminal region, thus disrupting the interaction between Nef and calnexin. Alanine substitution of basic residues at the N terminus of Nef has previously been shown to preserve membrane association and CD4 downregulation by Nef, 26 and intracellular localization of the mutant Nef was indistinguishable from that of Nef WT. 27 -COOH RKPRRE Figure 1 . Nef interacts with the cytoplasmic domain of calnexin. A, HA-tagged full-length and mutant calnexin constructs used for transfection. Green, blue, brown, and black boxes represent globular domain, tandem repeat motif (P domain), TM domain, and C-terminal cytoplasmic tail, respectively. Red boxes represent deleted fragments. CNX WT represents full length calnexin, CNX Δ504-586 has 81 of the 89 cytoplasmic tail residues deleted while maintaining the ER localization sequence RKPRRE; CNX Δ276-409 construct has 132 residues of the P domain deleted. B, HEK293T cells were cotransfected with vectors expressing Nef and HA-tagged CNX WT , CNX Δ504-586 , or CNX Δ276-409 and blotted for HA, Nef and GAPDH (lysate). Calnexin variants were immunoprecipitated 48 h post transfection using anti-HA coupled agarose beads (top) and resulting immunoprecipitates were immunoblotted for calnexin and Nef. Numbers under the lanes show relative amounts of coprecipitated Nef obtained by gel densitometry.
To verify the role of these residues in Nef interaction with calnexin, we used the mutant HIV-1 NL4-3 clone carrying Nef with Lys4 and Lys7 changed to valine and alanine, respectively (NefK). 27 Calnexin was immunoprecipitated from HEK293T cells transfected with WT or mutant HIV-1 clones, and the precipitate was immunoblotted for Nef. As shown in Figure 3A , interaction with calnexin was evident for Nef WT, but not for NefK. Interaction with the double mutant was reduced by 95%, indicating that the lysine residues in positions 4 and 7 are essential for Nef interaction with calnexin.
To look at the individual contribution of the 2 lysine residues to the interaction with calnexin, we mutagenized the Nef cons plasmid to create single and double lysine mutant constructs. To minimize variables introduced by cotransfection, we used HeLa cells that stably express ABCA1-GFP, transfected them with WT or mutant Nef constructs, and analyzed the amount of Nef that coimmunoprecipitates with calnexin. Based on densitometric analysis, interaction of calnexin with NefK4A was reduced by 80%, whereas interaction with NefK7A was reduced by 70% when compared with interaction with WT Nef ( Figure 3B ). Interaction of calnexin with double mutant NefK4,7A was undetectable. The reduced interaction observed with the Nef single mutants was sufficient to downregulate ABCA1, as shown in Figure 3C . NefK4A and NefK7A mutants reduced ABCA1 abundance as much as the WT Nef, whereas near-control level of ABCA1 was observed when both lysine residues were mutated ( Figure 3C ). This result highlights the importance of both residues in ABCA1 downregulation and suggests that under Nef overexpression conditions even reduced interaction with calnexin observed Docking model of the calnexin cytoplasmic domain (green)-Nef (magenta) interaction. The binding interface is formed by the Nef N-terminal α-helix, with Lys 7 and Arg 8, 19, and 22 forming interactions with calnexin. (c) Lys7 in Nef (magenta) displays strong interaction with Glu533 in calnexin (green) formed by the hydrogen and ionic bonds. (d) Lys4 plays a key role in the N-terminal region of Nef structure model (magenta). It forms a strong intramolecular interaction with Nef Asp90 with hydrogen and ionic bonds, supporting structural rigidity of the Nef N-terminal α-helix relative to the rest of Nef structure. B, Interactions in Nef-calnexin docking models mapped on Nef and calnexin sequences. Bars show the number of interactions, with the numbers for each maximum showing sequence number. In the Nef sequence, there are 3 distinct interaction clusters centered on residues 7, 22, 75, and 109, with sharp maxima for lysine 7, and arginines in positions 8, 19, 22, 75, and 109. Two interaction clusters in the calnexin sequence are formed by amino acids 528 to 533 and 545 to 557; they include glutamic acid residues in positions 529, 532, and 533.
for NefK4A and NefK7A mutants is sufficient for ABCA1 downregulation. It also supports conclusions of the previous study that demonstrated that Nef-calnexin interaction is essential for Nef-mediated retention of ABCA1 in ER and subsequent degradation. 5 To rule out the possibility that mutation of these residues grossly affected the behavior of the N-terminal domain of Nef, we tested the interaction of the mutant Nef with ABCA1. Previous studies demonstrated that interaction between Nef and ABCA1 also involves the N-terminal domain, 1 although the specific residues involved have not been identified. Co-precipitation analysis revealed ≈30% reduction in NefK4,7A interaction with ABCA1 as compared with ABCA1 interaction with WT Nef ( Figure 3D ). The reduction, however, remains in stark contrast to the >95% loss of interaction observed in the Nef-calnexin interaction studies ( Figure 3A) .
To visualize the effect of mutations on Nef-calnexin interaction, HEK293T cells were transfected with vectors expressing WT or mutant (NefK4,7A) Nef, stained with a combination of anti-Nef rabbit polyclonal and anticalnexin mouse monoclonal antibody followed by a combination of Alexa Fluor647 anti-rabbit IgG (green) and DyLight 550 antimouse IgG (red), counterstained with DAPI (blue), and analyzed by confocal fluorescent microscopy. Images were processed using Volocity software to identify colocalizing pixels (magenta staining). Consistent with our previous report, 5 WT Nef was colocalized with calnexin ( Figure 3E , left panels). However, the colocalization between calnexin and NefK4,7A was dramatically reduced ( Figure 3E , right panels), confirming the key role of these residues in Nef-calnexin binding.
Functional Analysis of Nef Mutants
In our previous study, we reported that Nef plays a central role in the downmodulation of ABCA1 expression and function. 1 This phenotype was associated with Nef's ability to interact with calnexin and disrupt calnexin interaction with ABCA1. 5 Identification of Nef residues required for interaction with calnexin provided an opportunity to verify the critical role of this interaction for the effects of Nef on cellular cholesterol metabolism. To assess the functional consequence of losing the Nef/calnexin interaction for ABCA1 functionality, we cotransfected HEK293T cells with ABCA1 and HIV-1 NL4-3 infectious clones that express either Nef WT or Nef K4VK7A (NefK). 27 Lysates were immunoblotted for ABCA1 Nef amino acid residues predicted in this study to form interactions with calnexin are compared with the interactions identified in experimental structures of complexes which include Nef. Comparison is done on the basis of structure/sequence alignments of the Nef model used to predict interactions with calnexin, and Protein Data Bank (PDB) experimental structures. Nef-interacting partners in the experimental structures are listed as they are given in the corresponding PDB files.
( Figure 4A ). Consistent with the results obtained with Nefexpressing vector ( Figure 3C ), total ABCA1 abundance was significantly reduced in the presence of Nef WT; however, the expression of ABCA1 in the presence of NefK was comparable to that of the control sample, which was transfected with an empty vector. This result is consistent with conclusions of the previous study that identified Nef as the key viral factor responsible for ABCA1 downregulation. 1 We further analyzed the effect of mutations disrupting Nef/calnexin interaction on the ability of Nef to downregulate apoA-1 specific cholesterol efflux. THP-1 cells were differentiated into macrophages using PMA and were infected A D E B C Figure 3 . Mutation of Nef lysine residues 4 and 7 blocks interaction with calnexin. A, HEK293T cells transfected with HIV-1 molecular clones encoding for Nef WT or Nef K4VK7A (NefK), or B, HeLa ABCA1 cells transfected with pcDNA plasmids expressing Nef WT or mutants Nef K4A, Nef K7A, or NefK4,7A were lysed 48 h post transfection. Endogenous calnexin was immunoprecipitated using monoclonal anti-calnexin antibody and immunoprecipitates were blotted for Nef and calnexin (top). Whole-cell lysates were analyzed for expression of calnexin, Nef, and GAPDH (bottom). Numbers under the Nef panels show relative amounts of coprecipitated Nef obtained by gel densitometry. C, HeLa-ABCA1-GFP cells were transfected with Nef WT or mutants Nef K4A, Nef K7A, or Nef K4,7A. Cells were lysed 48 h post transfection and lysates were analyzed for expression of ABCA1, Nef, and GAPDH. Numbers under the ABCA1 panel show relative amounts of ABCA1 obtained by gel densitometry. D, HEK293T cells were cotransfected with ABCA1-FLAG and Nef WT or NefK4,7A and were lysed 48 h post transfection. ABCA1 was immunoprecipitated using anti-FLAG beads and precipitates were blotted for ABCA1 and Nef (top with HIV-1 expressing either WT Nef or NefK. Given that the virus used in this experiment was the X4-tropic strain NL4-3, we pseudotyped it with vesicular stomatitis virus-G to ensure 1-cycle replication. Both Nef WT and NefK viruses successfully infected the cells, establishing similar levels of Nef expression ( Figure 4B, a) . Seven days after infection, cholesterol efflux assay was performed. In agreement with previous reports, 1,5,28 cells infected with the WT virus had significantly reduced cholesterol efflux relative to mock-infected cells (Figure 4Bb ). However, infection with the virus carrying NefK did not lead to efflux decrease.
Interaction Between Nef and Calnexin Is Direct
To test whether Nef and calnexin interact directly with each other, we expressed calnexin and the cytoplasmic tail of calnexin (Calnexin-CT) in Escherichia coli and purified recombinant proteins by column chromatography. For the purification of full-length calnexin, we have developed and implemented a novel purification system based on the ultrahigh affinity (K d ≈10 -14 -10 -17 M) small protein complex of genetically inactivated colicin 7 DNAse (CL7) and its inhibitor, immunity protein 7 (Im7). [29] [30] [31] [32] We have attached a CL7 variant, which possesses no DNAse activity but retains full Im7 affinity, as a C-terminal tag on His-tagged calnexin construct ( Figure 5A,  left) . A cleavage site for the prescission protease (PSC) inserted between calnexin and CL7 allowed for the elution of calnexin from the Im7 column through cleavage by PSC. A single purification step provided an excellent yield of ≈90% pure protein ( Figure 5A ), in which major contamination represented calnexin molecules (confirmed by mass spectroscopy), most likely, truncated from the N terminus. The Calnexin-CT construct was designed with a single N-terminal His-tag and was purified using the standard procedure ( Figure 5A, right) . Binding of myristoylated Nef SF2 33 to calnexin and its cytoplasmic domain was analyzed using surface plasmon resonance ( Figure 5B ). Calnexin and calnexin-CT were immobilized on microchip surfaces and myristoylated Nef was injected over the surface. Nef SF2 directly bound to calnexin with an affinity (K D ) of 89.1 nmol/L (k a =1.338E5 M -1 s -1 , k d =0.01192 s -1 , χ 2 =2.77 RU; Figure 5B , left panel). Binding to calnexin-CT was observed to have higher affinity of K D =9.4 nmol/L (k a =9.083E5 M -1 s -1 , k d =0.008569 s -1 , χ 2 =0.474 RU; Figure 5B , right panel). Taken together, these experiments demonstrate that Nef/calnexin interaction is direct and involves the cytoplasmic domain of calnexin.
Virtual Screening for Compounds Interfering With Nef-Calnexin Interaction
Docking-based virtual screening has been performed on compounds from the Zinc NCI Plated 2007 data set with docking program Vina. 34 Nef model described in Figure 2 has been used with the interaction site for ligand docking selected to cover amino acid residues Lys4 and Lys7. The data set consisted of 139 735 compounds. Ten putative ligands were identified and prioritized according to the Vina ranking, and structural alignment of these compounds to the Nef-calnexin complex is shown in Figure 6A (a). The model shows that these compounds can block Nef/calnexin interaction at the calnexin residues Glu529, Glu532, and Glu533. Docking of NSC 13987, which turned out in the later studies to be the most effective inhibitor of the Nef-calnexin interaction, is shown in panel b ( Figure 6A ). Interactions of the compound with Nef include 2 hydrogen bonds with Nef amino acid residues Ser6 and Tyr124. Three of the 10 compounds, NSC 1758, NSC 13987, and NSC 92938, have been submitted for experimental testing. The chemical names and molecular structures of these compounds are shown in Figure 6B .
Testing the Compounds' Activity
To test whether the compounds identified in our virtual screen can interfere with Nef-calnexin interaction, we first performed coimmunoprecipitation assay. HEK293T cells were transfected with plasmid encoding for Nef cons and 6 hours post transfection were treated with NSC 1758 (4 μmol/L), NSC 13987 (5 μmol/L), or NSC 92938 (5 μmol/L). These concentrations of the compounds were determined by the MTT assay to reduce cell metabolism by <10% during 5-day incubation ( Figure 6C) . Among the 3 compounds tested, 1 compound, NSC 13987, inhibited coimmunoprecipitation of Nef and calnexin by over 50%, whereas the effect of NSC 1758 and NSC 92 938 showed a partial inhibition of Nef/calnexin binding, which did not reach statistical significance ( Figure 6D) . We have previously shown that membrane localization of Nef is important for the interaction of Nef with calnexin. 5 To rule out the possibility that the compound interferes with membrane localization of Nef, we tested whether NSC 13987 affects the interaction between Nef and ABCA1, as ABCA1-Nef interaction also requires membrane localization of Nef. 1 As shown in Figure 6E , ABCA1-Nef interaction remained unaffected in the presence of compound indicating that the inhibition was specific for the molecular interaction of Nef and calnexin.
We next tested whether the 3 compounds could prevent the impairment of cholesterol efflux by Nef. THP-1 cells were transfected with a Nef-encoding plasmid, and drug treatment was started 6 hours after transfection. The following day, cells were activated with PMA after which cholesterol efflux assay was performed. Drug treatment was continued throughout the duration of the experiment. Figure 7Aa shows cholesterol efflux measured in untreated cells or cells treated with DMSO or each of the 3 compounds. Cholesterol efflux in Nef-transfected untreated or DMSO-treated cells was reduced by over 2-fold relative to mock-transfected cells. NSC 13987, which showed the inhibition of Nef-calnexin interaction ( Figure 6D ), significantly increased cholesterol efflux as compared with DMSO-treated Nef-expressing cells, although the rescue was partial and did not completely reverse the inhibition. Two other compounds did not significantly rescue Nefsuppressed cholesterol efflux. Treating untransfected THP-1 cells with the compounds did not lead to any changes in cholesterol efflux (Figure 7Ab ). This result implies that the impact in efflux capacity observed in the presence of NSC 13987 was specific to the compound's activity in Nef-expressing cells. It also demonstrates that the compounds were not toxic to cells.
To test the effect of NSC 13987 in the context of natural infection, we infected monocyte-derived macrophages (MDM) with HIV-1 ADA, treated them with NSC 13987 and measured cholesterol efflux. Viral replication in the presence of the compound was reduced (Figure 7Ba ), and fold change analysis showed on average a 2-fold reduction in reverse transcriptase (RT) activity measured in 3 independent experiments with cells from different donors (Figure 7Bb ), consistent with demonstrated rescue by the compound of Nef-inhibited cholesterol efflux ( Figure 7A ) and previous studies demonstrating anti-HIV activity of ABCA1 and ABCA1-stimulated cholesterol efflux. 28, 35, 36 Consistent with previous studies, 1, 5, 36 cholesterol efflux from HIV-infected cells was decreased by 60%, whereas HIV-infected cells treated with NSC 13987 showed cholesterol efflux not significantly different from that of Figure 6 continued. NSC 92938, and lysed. Nef was immunoprecipitated using anti-HA agarose beads and bound complexes were immunoblotted for Nef and calnexin (left labeled IP: αHA). Densitometric quantification of calnexin coimmunoprecipitated with Nef is presented in the right. Results are presented as mean±SD of 3 independent experiments, and p values are shown above the bars. Whole cell lysates were analyzed for amount of calnexin, Nef, and GAPDH (left labeled Lysate). E, HEK293T cells were cotransfected with ABCA1-FLAG and Nef cons and treated with compound NSC 13987. Cells were lysed 48 h post transfection and ABCA1-FLAG was immunoprecipitated using anti-FLAG beads. Precipitated complexes were blotted for ABCA1 and Nef (top). Input amount was analyzed from whole cell lysates by immunoblotting for ABCA1, Nef, and GAPDH (bottom). mock-infected cells (Figure 7Ca ). Fold change in cholesterol efflux from 2 independent experiments with cells from different donors showed consistent efflux rescue by the compound (Figure 7Cb) . A more potent reversal by NSC 13987 of cholesterol efflux inhibited by HIV-1 infection ( Figure 7C ) than by Nef transfection (Figure 7Aa ) is likely because of higher levels of Nef expression in transfected cells, and a combined effect of reduced virus replication and inhibition of the Nefcalnexin interaction in HIV-infected cells.
Lack of a small animal model of HIV-associated atherosclerosis prevented us from testing the antiatherogenic potential of NSC 13987 in vivo. We therefore used the best available in vitro approximation of HIV-associated proatherogenic changes, conversion of HIV-infected macrophages into the foam cells. 1 In this experiment, we used the vesicular stomatitis virus G protein-pseudotyped HIV-1 NL4-3 and its Nef-deficient mutant (HIV-1∆Nef), which can go through only 1 cycle of replication in MDM cultures. This approach allowed us to eliminate the drug's effect on viral replication, leaving changes in cholesterol metabolism as the only cause of potential effects on lipid droplets accumulation. Indeed, virus replication, as measured by RT activity in culture supernatants, was 400 to 500 cpm/μL for both WT and ∆Nef viruses treated or untreated with NSC 13987. As revealed by bright field microscopy, MDM cultures infected with WT HIV-1 (Figure 7Da (Figure 7Da, bottom left panel) , indicating that the observed effect was mediated by Nef expression. Of note, treatment with NSC 13987 of mock-infected MDM or MDM infected with the ∆Nef virus did not decrease lipid droplets, indicating the compound's effect was dependent on Nef. Quantitative analysis of the images performed on 55 cells from each condition is presented in Figure 7Db . Histograms in the left panel demonstrate a shift of RGB pixel distribution to low-intensity area (indicative of reduction of ORO-stained lipid droplets) in MDMs infected with WT HIV-1 and treated with NSC 13987 relative to HIV-infected untreated culture, whereas treatment of mock-infected cultures or cultures infected with the ∆Nef virus did not significantly affect pixel distribution. Importantly, histograms obtained with HIV-infected cells treated with NSC 13987 were similar to those with mock-infected cells, indicating that the drug fully reversed HIV-induced accumulation of lipid droplets. The pie-chart graphs on the right show the distribution of cells according to ORO-stained area; 65% of HIVinfected cells had over 20% of cell area stained with ORO, whereas such cells constituted only 42% and 44% in mockand HIV-1∆Nef-infected MDMs, respectively. NSC 13987 reduced the percentage of such cells in HIV-infected MDM to 22%, which was even smaller in drug-treated uninfected cells.
To better visualize lipid droplets, we used fluorescent microscopy. We also used macrophage-tropic HIV-1 isolate ADA to better mimic natural conditions. The diameter of ORO-stained lipid droplets in HIV-infected cells varied from 0.1 to 3 μm (Figure 7Dc, middle panel) . The size of lipid droplets accumulated in HIV-infected MDMs treated with NSC 13987 was visibly reduced and did not exceed 0.5 μm (right panel); in fact, it was similar to the size of the droplets in mock-infected cells (left panel).
Taken together, these results provide a proof of concept for the idea that HIV-induced impairment of cholesterol efflux can be reversed pharmacologically by blocking the Nef/calnexin interaction.
Discussion
Highly active anti-retroviral therapy (HAART) has transformed the treatment of the HIV disease changing the prognosis from acutely lethal to chronic illness, and lifespan of HIV-infected subjects approximates that of uninfected individuals. However, highly active anti-retroviral therapy does not cure HIV, and chronic HIV infection is associated with several comorbidities, such as premature atherosclerosis and cardiovascular disease. 37 An essential component in pathogenesis of cardiovascular disease in HIV-infected subjects is HIV-associated dyslipidemia, which is caused both by drugs used to treat HIV infection and by the effects of HIV itself on cholesterol metabolism. 38 In this report, we identify a smallmolecule compound that blocks HIV-mediated impairment of cellular cholesterol metabolism. Excitingly, this compound also inhibited the replication of HIV, suggesting that, if developed into a drug, it can target both HIV infection and virusinduced metabolic comorbidities.
Our previous studies demonstrated that HIV critically depends on the interaction with host cholesterol metabolism and modifies it for the optimization of viral replication. 1, 2, 28, 35, 36 Specifically, HIV, through viral protein Nef, reduces abundance and impairs functional activity of ABCA1, a key transporter in cholesterol efflux pathway. 1 As a result, host cells accumulate excessive cholesterol promoting the formation of plasma membrane lipid rafts, which are sites of HIV entry, assembly, and budding. 39 Recently, we demonstrated that an important mechanism of downregulation and functional impairment of ABCA1 by HIV is Nef-mediated inhibition of the interaction between ABCA1 and the ER chaperone, calnexin. 5 This study provides the first characterization of the exact molecular structures involved in Nef-calnexin interaction.
First, we established that the interaction between Nef and calnexin involves the cytoplasmic domain of calnexin. Although this finding is consistent with demonstrated localization of Nef to the cytoplasmic side of membranes 27 and lack of evidence for Nef localization to ER, it is surprising given that the C-tail of calnexin is not involved in the interaction between calnexin and ABCA1, which is disrupted by Nef. 5 Indeed, calnexin interactions with glycosylated proteins are mediated by its lumenal domains. 12 Therefore, Nef interaction with the C-tail alters the activity of the lumenal domains of calnexin. How Nef is doing it is unknown and several possibilities can be considered. Binding of Nef may prevent posttranslational modifications of the C-tail of calnexin, such as phosphorylation on Ser563 that has been shown to regulate calnexin interaction with α1-antitrypsin and several other glycoproteins. 15 However, docking analysis did not reveal Ser563 as a likely site for interaction with Nef ( Figure 5B) . The same argument can be applied to SUMOylation (small ubiquitin-like modifier) at Lys506, which has been shown to regulate calnexin interaction with another ER protein, protein tyrosine phosphatase 1B 40 : Lys506 is not among the preferred sites for Nef binding. It is likely that Nef binding to the cytoplasmic domain of calnexin results in signal transduction from the cytoplasmic to the lumenal domain, eg, via a conformational change in calnexin. This explanation is consistent with the partial reduction of Nef binding to calnexin carrying deletion in the lumenal domain ( Figure 1B) , which may be because of reverse signaling from lumenal to cytoplasmic domain. Mechanistic details of such an effect await careful structural analysis. Regardless of the mechanism, this finding provides the first example of a pathogen utilizing the calnexin C-tail to regulate functional activity of this chaperone.
Second, we identified the Nef residues critical for interaction with calnexin: mutation of lysine residues in positions 4 and 7 of Nef abrogated Nef-calnexin binding, prevented ABCA1 downregulation, and restored cholesterol efflux in cells infected with HIV-1. Our finding that Nef-calnexin interaction involves the flexible N-terminal region of Nef was surprising, as this region has not been implicated before in protein-protein interactions (Table) . However, molecular modeling ( Figure 2 ) suggests that Lys4 of Nef forms a hydrogen bond with Asp90 located in an α-helix, thus contributing to stabilization of the structure of the N-terminal region, and therefore acts as a structural anchor for the Nef Lys7 interaction with calnexin. Nef Lys7 is predicted to form a strong interaction with Glu533 in calnexin through the hydrogen and ionic bonds. Thus, mutation of both lysine residues destabilizes the structure of Nef, and cancels the strong interaction with calnexin provided by Lys7, which explains the dramatic effect of these mutations on Nef-calnexin interaction. The N-terminal region of Nef has not been involved in proteinprotein interactions, but its basic and hydrophobic residues were shown to be essential for membrane association of Nef. 41 Interestingly, lysine residues at positions 4 and 7, which participate in interaction with calnexin, were not essential for the membrane association of Nef. 42 Therefore, our study identified a novel epitope on Nef involved in the interaction with the cytoplasmic tail of calnexin.
Using this information, we performed virtual screening for compounds that can potentially disrupt Nef-calnexin interaction, and identified several candidates. One of these compounds, 1[(7-Oxo-7H-benz[de]anthracene-3-yl)amino] anthraquinone (NSC 13987), prevented coprecipitation of calnexin with Nef, reversed Nef-mediated effect on ABCA1 abundance, and restored cholesterol efflux impaired by Nef, thus effectively reversing the effects of Nef on host cholesterol metabolism. In addition, the compound resulted in a near 2-fold inhibition of viral replication ( Figure 7B ). This latter effect may have 2 main explanations. First, the compound prevents ABCA1 downregulation by Nef, and ABCA1 has been shown to inhibit HIV-1 replication by reducing lipid rafts' abundance on the plasma membrane and affecting the production and infectivity of nascent virions. 3, 28, 35, 36 Second, previous reports presented evidence that anthraquinone derivatives inhibit the ribonuclease H function of HIV-1 reverse transcriptase. 43, 44 Therefore, the action of compound NSC 13987 in HIV-1-infected cells may be a combination of inhibiting Nef-calnexin interaction and a separate antiviral activity. This, together with differences in Nef expression, could explain why the rescue of the cholesterol efflux by the compound was only partial in Nef-transfected cells (Figure 7Aa ), but almost complete in HIV-infected macrophages ( Figure 7C ). Our findings provide the basis for using NSC 13987 as a foundation for the development of novel treatment approaches for HIV-associated atherosclerosis and other Nef-dependent metabolic comorbidities. Indeed, the effects of Nef secreted from HIV-infected cells may be responsible for many lipidrelated complications of HIV disease, such as atherosclerosis, diabetes mellitus, lipodistrophy, and neurodegeneration, so the compounds similar to the one identified in this study may reverse HIV-induced impairment of cholesterol metabolism in uninfected cells mitigating lipid-related complications of HIV infection.
Unfortunately, no small animal model is available to test in vivo whether NSC 13987 reverses the development of atherosclerosis associated with HIV infection. Indeed, mice do not develop atherosclerosis unless certain genes (apoE or ldlr) are knocked out, and humanization of such mutant mice to make them susceptible to HIV infection has not been attempted. Injection of Nef into mice reproduces only some features of the disease and it remains uncertain whether these effects of Nef involve calnexin. 4 Here, we demonstrated that NSC 13987 inhibits the accumulation of lipid droplets in HIV-infected macrophage cultures ( Figure 7D ), which is a characteristic feature of foam cells, and foam macrophages are a hallmark of the development of atherosclerosis. 45 Our findings indicate that the effect of NSC 13987 is specific for Nef-expressing cells, as the compound did not affect lipid droplets in mockinfected macrophages or cells infected with Nef-deficient HIV-1 ( Figure 7D ). This result supports our conclusion that the protective effect of NSC 13987 is because of the inhibition of Nef-calnexin interaction, rather than to an off-target effect on cholesterol metabolism.
Calnexin is an ER-integral membrane protein and is responsible for the folding of several glycoproteins. Depletion of calnexin has been shown to result in the elevation of several other ER-folding factors minimizing aberrant protein folding and expression. 46 This is mainly true for glycoproteins which are common substrates of other soluble ER chaperones like calreticulin. However, solubility and oligosaccharide variability impose a limit on this commonality, making calnexin vital for expression and function of proteins like ABCA1 and several others. 5, 47, 48 Nef's ability to target several host factors, such as CD4, MHC I, and CXCR4, may in part be because of the limitation Nef imposes on the access of these proteins to calnexin. Therefore, the protective effect of compound NSC 13987 may well extend to restoring the expression and function of other proteins targeted by Nef.
In conclusion, in this study we identified the molecular mechanisms and structural epitopes involved in interaction between HIV-1 Nef and host calnexin and characterized a September 2016 compound capable of reversing the effects of Nef, thus presenting potential utility in treatment of HIV-1 infection and its metabolic side effects.
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